Other
Neoadjuvant Immunotherapy
0
Pipeline Programs↗
9
Active Trials↗
0
Companies Involved↗
Neoadjuvant Immunotherapy is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
15
clinical trials
Recruiting7 · 47%
Completed2 · 13%
Unknown status2 · 13%
Terminated1 · 7%
Active, not recruiting1 · 7%
Withdrawn1 · 7%
Other1 · 7%
Clinical Trials
Trial Activity
15 trials
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05914389·100 enrolled
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Recruiting·—·Phase 2·NCT05515796·200 enrolled
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
Recruiting·—·N/A·NCT06317558·4,000 enrolled
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer
Not yet recruiting·—·Phase 2·NCT07409844·152 enrolled
Neoadjuvant Immunotherapy in Brain Metastases
Terminated·—·Phase 2·NCT04434560·1 enrolled
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04943029·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)